The Texas Pharmacy Association (TPA) has been awarded a grant from the Community Pharmacy Foundation (CPF) and Texas Department of State Health Services (DSHS) to develop and implement new community-based healthcare provider digital linkages with pharmacists that include support resources and a strong business infrastructure. Utilizing a cloud-based system, physicians will be able to refer patients with uncontrolled hypertension to a community-based pharmacist network who will deliver services ...
READ MORE
|
Aurinia Pharmaceuticals announced on Dec. 19, 2016 that the company has entered into a long-term agreement with Lonza for the manufacture of voclosporin API. This agreement follows a multi-year clinical manufacturing relationship where the companies have refined the process and analytical methods to produce clinical and commercial supplies of voclosporin. Under the terms of the agreement, Lonza will produce cGMP-grade voclosporin drug substance for use in Aurinia’s Phase III lupus nephritis (LN)...
PHARMTECH.COM
READ MORE
|
New research, which appears in the journal Nature Communications, shows that delivering two small molecules to mice helps their hearts regenerate after a heart attack. Heart disease is the leading cause of death in the United States and responsible for almost 1 in 4 deaths in the country. An adverse cardiovascular event, such as a heart attack, typically damages the cells that make up the heart muscle. These cells are called cardiomyocytes, and losing them puts people at risk of heart failure &m...
READ MORE
|
The U.S. Food and Drug Administration (FDA) approved Bridgewater, NJ-based Amneal Pharmaceuticals’ generic version of Novartis’ Exelon Patch (Rivastigmine Transdermal System) for dementia related to Alzheimer’s and Parkinson’s diseases. The two companies were involved in patent litigation over the Exelon Patch in 2015 and 2016, but the two companies worked out a deal in October 2016. Shortly afterward, in November 2016, there were rumors that Novartis was considering acqu...
READ MORE
|
Clarify Health, a leading healthcare analytics company, announced that its life sciences software, Clarify Launch, now includes innovative enhancements that give brand teams a faster and more effective way to identify market opportunities to drive growth. The ability to explore over 300 million longitudinal patient care journeys using Clarify Launch offers brand teams rapid access to actionable insights within specific patient populations. Clarify brings first-of-their-kind patient segmentation,...
BUSINESS WIRE
READ MORE
|
The impact of interruption of anti-osteoporosis treatment in patients on therapy with bisphosphonates or denosumab is reviewed in a new International Osteoporosis Foundation (IOF) working group paper 'Fracture risk following intermission of osteoporosis therapy' published in the journal Osteoporosis International. The widespread practice of recommending one to two year 'drug holidays' arose following concerns that long-term use of bisphosphonates is associated with rare side effe...
READ MORE
|